C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

C1 Inhibitor Treatment Registry to Assess the Safety and Immunological Profile of Ruconest in the Treatment of HAE Attacks

This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.

see below

Inclusion Criteria:

• Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH)
• Patients must give written informed consent

Exclusion Criteria:

• A diagnosis of acquired C1INH deficiency (AAE)